Clinical trials: Healthy Volunteers Overweight
Obese But Otherwise Healthy Participants
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will…
- Trial name
- CANYON-1 (NCT07310901)
- Testing
- CRB-913
- Where
- 15 sites in United States
- Volunteers
- 254 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Healthy Volunteers, Obesity
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWN117 injection in healthy and…
- Trial name
- NCT07824804
- Testing
- MWN117
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy, Liver Diseases
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts.
- Conditions
- Healthy, Liver Diseases, Obesity
- Trial name
- NCT05296733
- Testing
- BI 456906
- Where
- 13 sites in United States, Germany and 4 more
- Volunteers
- 82 people
- Sponsor
- Boehringer Ingelheim
Obesity
An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
The goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are: Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple…
- Trial name
- NCT06891287
- Testing
- RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- RANI Therapeutics
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight or Obesity
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
This Phase I, active-controlled, randomised trial will be conducted in 2 parts. Part I aims to confirm the PD equivalence of EMP22 and Xenical® based on percent fecal fat excretion at steady state.
- Trial name
- NCT06013163
- Testing
- Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical®
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Healthy, Obesity
A Study of LY3971297 in Healthy Participants
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP).
- Conditions
- Healthy, Obesity, Hypertension
- Trial name
- NCT06148272
- Testing
- LY3971297, LY3971297 IV
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers, Overweight
Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People
The study looks at how the study medicine (NNC9204-1177) affects other medicines in the body. Participants will get the study medicine and 5 other medicines which have all been approved by the authorities.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04059367
- Testing
- NNC9204-1177, Cocktail of 5 already approved drugs
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.
- Trial name
- NCT04493567
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.
- Trial name
- NCT05406115
- Testing
- AMG 786
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Amgen
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
Safety Study to Evaluate BMS-830216 in Healthy Subjects
The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects
- Trial name
- NCT00878020
- Testing
- BMS-830216
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Overweight , Obesity
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal…
- Trial name
- NCT07443059
- Testing
- Zovaglutide
- Where
- 3 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Participants
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
This Phase 1, first-in-human study will evaluate the safety and tolerability of SUN-0864, how the body processes SUN-0864, and how SUN-0864 affects the body in healthy adults and otherwise healthy adults who are overweight or…
- Trial name
- NCT07905560
- Testing
- SUN-0864 (Formulation 1) or SUN-0864 (Formulation 2)
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Superluminal Medicines, Inc.
Safety, Healthy Subjects
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent
- Trial name
- NCT03385369
- Testing
- MEDI0382
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy Volunteer
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
- Trial name
- NCT07514260
- Testing
- ABBV-295
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AbbVie
Healthy Subjects;Overweight or Obesity
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety…
- Trial name
- NCT07784699
- Testing
- GZC8072 Tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S